• metastatic/advanced mGC or mGEJC
• mGC or mGEJC - 1st line (L1)
• mGC or mGEJC - L1 - all population
• mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2
• mGC or mGEJC - L1 - HER2 negative 1
• mGC or mGEJC - L1 - HER2 positive
• mGC or mGEJC - L1 - PDL1 positive 4
• mGC or mGEJC - 2nd Line (L2)
• mGC or mGEJC - L2 - all population 4
• mGC or mGEJC - L2 - PDL1 positive 1
• mGC or mGEJC - maintenance (M)
• mGC or mGEJC - M - HER2 negative 1
• mGC or mGEJC - M - HER2 neg/PDL1 positive 1
• gene alteration defined cancer

 

• gene alteration target therapy
• EGFR gene alteration
• amivantamab-vmjw
• mobocertinib
• FGFR (2/3) gene alteration targeted therapy
• erdafitinib
• infigratinib
• KRAS gene alteration targeted therapy
• sotorasib
• NTRK gene alteration targeted therapy
• larotrectinib
• RET gene alteration targeted therapy
• pralsetinib
• selpercatinib
• HER inhibitor
• EGFR inhibitor
• dacomitinib
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib
• rucaparib

• versus all
• vs HER inhibitor
• vs EGFR inhibitor
• vs gefitinib based treatment
• vs gefitinib alone
• vs non active control
• vs no control (uncontrolled study)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)